Senores Pharma IPO: GMP, subscription status, review, other details. Apply or not?
Senores Pharma IPO Apply or not: The Senores Pharmaceuticals’ public issue will close for public bidding on Tuesday, December 24. The IPO has received 1.78x subscription on Day 1, as of last week Friday.
Senores Pharma IPO latest GMP
As of December 22, the grey market premium (GMP) for the Senores Pharmaceutical public issue stands at ₹200 per share. With the upper price band for the IPO at ₹391, the shares are expected to be listed at ₹591 per share, a premium of 51.15 per cent, according to the data collected from Investorgain.com.
Grey market premium (GMP) is the investors’ willingness to pay more for a public issue. The GMP increased to ₹200 on December 21 and is maintaining that level, compared to its December 20 level of ₹190.
Strength
- Senores Pharmaceuticals has a US FDA-approved manufacturing facility in Atlanta, enhancing its ability to serve regulated markets.
- The company’s Atlanta facility, approved by the DEA, can manufacture controlled substances, providing a competitive edge in the US market.
- Senores Pharmaceuticals offers a one-stop CDMO solution, catering to pharmaceutical companies’ development and manufacturing needs.
- The company has built a strong product portfolio in emerging markets, focusing on complex products with less competition.
Company Promoter(s)
- Swapnil Jatinbhai Shah
- Ashokkumar Vijaysinh Barot
